Cost-effectiveness of inhaled steroids in asthma: Impact of effect on bone mineral density

Journal of Allergy and Clinical Immunology

Volumn 117, Issue 2, 2006, Pages 359-366

  Fuhlbrigge, Anne L ^a,d   Bae, Seung Jin ^c   Weiss, Scott T ^a,e   Kuntz, Karen M ^c   Paltiel, A David ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CHANNING LABORATORY   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Bone density; Cost effectiveness; Drug toxicity; Hip fracture; Inhaled corticosteroids; Markov models; Osteoporosis; Treatment outcome

Indexed keywords

CORTICOSTEROID; STEROID;

ADULT; ARTICLE; ASTHMA; BONE DENSITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEALTH CARE COST; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; ASTHMA; BONE DENSITY; COST-BENEFIT ANALYSIS; FEMALE; HIP FRACTURES; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 32044445806     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2005.10.036     Document Type: Article

References (50)

1. National Asthma Education and Prevention Program Expert Panel Report 2: guidelines for the diagnosis and management of asthma 1997 National Institutes of Health Bethesda (MD) Pub no 97-4051
2. R.J. Adams, A. Fuhlbrigge, J.A. Finkelstein, P. Lozano, J.M. Livingston, and K.B. Weiss Use of inhaled anti-inflammatory medication in children with asthma in managed care settings Arch Pediatr Adolesc Med 155 2001 501 507
3. A.L. Fuhlbrigge, R.J. Adams, T.W. Guilbert, E. Grant, P. Lozano, and S.L. Janson The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines Am J Respir Crit Care Med 166 2002 1044 1049
4. R.J. Martin, S.J. Szefler, V.M. Chinchilli, M. Kraft, M. Dolovich, and H.A. Boushey Systemic effect comparisons of six inhaled corticosteroid preparations Am J Respir Crit Care Med 165 2002 1377 1383
5. A.D. Paltiel, A.L. Fuhlbrigge, B.T. Kitch, B. Liljas, S.T. Weiss, and P.J. Neumann Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model J Allergy Clin Immunol 108 2001 39 49
6. M.T. Halpern, J.K. Schmier, M.D. Van Kerkhove, M. Watkins, and C.J. Kalberg Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis Ann Allergy Asthma Immunol 92 2004 201 207
7. S. Suissa, M. Baltzan, R. Kremer, and P. Ernst Inhaled and nasal corticosteroid use and the risk of fracture Am J Respir Crit Care Med 169 2004 83 88
8. R.B. Hubbard, C.J. Smith, L. Smeeth, T.W. Harrison, and A.E. Tattersfield Inhaled corticosteroids and hip fracture: a population-based case-control study Am J Respir Crit Care Med 166 2002 1563 1566
9. T.P. van Staa, H.G. Leufkens, and C. Cooper Use of inhaled corticosteroids and risk of fractures J Bone Miner Res 16 2001 581 588
10. A.E. Tattersfield, G.I. Town, O. Johnell, C. Picado, M. Aubier, and P. Braillon Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years Thorax 56 2001 272 278
11. C.A. Wong, L.J. Walsh, C.J. Smith, A.F. Wisniewski, S.A. Lewis, and R. Hubbard Inhaled corticosteroid use and bone-mineral density in patients with asthma Lancet 355 2000 1399 1403
12. E. Israel Effects of inhaled glucocorticoids on bone density in premenopausal women N Engl J Med 345 2001 941 947
13. A. Jones, J.K. Fay, M. Burr, M. Stone, K. Hood, and G. Roberts Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease Cochrane Database Syst Rev 2002 CD003537
14. T.C. Medici, E. Grebski, M. Hacki, P. Ruegsegger, C. Maden, and J. Efthimiou Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects Thorax 55 2000 375 382
15. J.J. Egan, C. Maden, S. Kalra, J.E. Adams, R. Eastell, and A.A. Woodcock A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years Eur Respir J 13 1999 1267 1275
16. J.T. Li, L.B. Ford, P. Chervinsky, S.C. Weisberg, D.J. Kellerman, and K.G. Faulkner Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma J Allergy Clin Immunol 103 1999 1062 1068
17. J.A. Hughes, B.G. Conry, S.M. Male, and R. Eastell One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density Thorax 54 1999 223 229
18. A. Struijs, and H. Mulder The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide Neth J Med 50 1997 233 237
19. R.A. Pauwels, J.C. Yernault, M.G. Demedts, and P. Geusens Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group Am J Respir Crit Care Med 157 1998 827 832
20. A. Fuhlbrigge, A.D. Paltiel, B. Kitch, Rashti, S.T. Weiss, and S.J. Lee Cost-effectiveness of inhaled steroids in asthma: impact of effects on BMD Am J Respir Crit Care Med 167 2003 A38
21. C. Cooper, and L. Melton Jr. Epidemiology of osteoporosis Trends Endocrinol Metab 3 1992 224 229
22. L. Melton Jr., S.H. Kan, H.W. Wahner, and B.L. Riggs Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age J Clin Epidemiol 41 1988 985 994
23. R.D. Wasnich Epidemiology of osteoporosis M.J. Favus S. Christakos Primer on the metabolic bone diseases and disorders of mineral metabolism 4th ed. 1999 Lippincott Williams & Wilkins Philadelphia (PA) 257 259
24. R.A. Pauwels Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med 340 1999 1948 1953
25. Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 2000 1902 1909
26. M.R. Gold J.E. Siegel L.B. Russel M.C. Weinstein Cost-effectiveness in Health and Medicine. Report of the Panel on Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
27. M.L. Moy, A.L. Fuhlbrigge, K. Blumenschein, R.H. Chapman, A.J. Zillich, and K.M. Kuntz Association between preference-based health-related quality of life and asthma severity Ann Allergy Asthma Immunol 92 2004 329 334
28. A.N. Tosteson, S.E. Gabriel, M.R. Grove, M.M. Moncur, T.S. Kneeland, and L. Melton Jr. Impact of hip and vertebral fractures on quality-adjusted life years Osteoporos Int 12 2001 1042 1049
29. D.H. Solomon, and K.M. Kuntz Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? a cost-effectiveness analysis Arthritis Rheum 43 2000 1967 1975
30. Bureau of Labor Statistics Consumer Price Index (CPI) detailed report 2004 US Department of Labor
31. V. LoCascio, E. Bonucci, B. Imbimbo, P. Ballanti, S. Adami, and S. Milani Bone loss in response to long-term glucocorticoid therapy Bone Miner 8 1990 39 51
32. S.D. Ramsey Surgical and endoscopic therapy for COPD: the NETT and beyond 2004 American Thoracic Society Annual Conference Orlando (FL)
33. Harvard Center for Risk Analysis The CEA Registry: standardizing the methods and practices of cost-effectiveness analysis 2005 Harvard School of Public Health Boston
34. H. Powell, and P.G. Gibson High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children Cochrane Database Syst Rev 4 2005
35. N.H. Gershman, H.H. Wong, J.T. Liu, and J.V. Fahy Low- and high-dose fluticasone propionate in asthma; effects during and after treatment Eur Respir J 15 2000 11 18
36. T.P. van Staa, H.G. Leufkens, L. Abenhaim, B. Zhang, and C. Cooper Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatology (Oxford) 39 2000 1383 1389
37. C.A. Wong, G. Subakumar, and P.M. Casey Effects of asthma and asthma therapies on bone mineral density Curr Opin Pulm Med 8 2002 39 44
38. D.B. Allen, L. Bielory, H. Derendorf, R. Dluhy, G.L. Colice, and S.J. Szefler Inhaled corticosteroids: past lessons and future issues J Allergy Clin Immunol 112 2003 S1 S40
39. C.A. Sorkness Establishing a therapeutic index for the inhaled corticosteroids, part II: comparisons of systemic activity and safety among different inhaled corticosteroids J Allergy Clin Immunol 102 1998 S52 S64
40. G.R. Todd, C.L. Acerini, J.J. Buck, N.P. Murphy, R. Ross-Russell, and J.T. Warner Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate Eur Respir J 19 2002 1207 1209
41. N. Adams, J. Bestall, and P.W. Jones Budesonide for chronic asthma in children and adults 2002 The Cochrane Library Oxford, UK
42. J.P. Kemp, S. Osur, S.B. Shrewsbury, N.E. Herje, S.P. Duke, and S.M. Harding Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial Mayo Clin Proc 79 2004 458 466
43. B.L. Riggs, and L. Melton Jr. Involutional osteoporosis N Engl J Med 314 1986 1676 1686
44. US Preventive Services Task Force Screening for osteoporosis in postmenopausal women: recommendations and rationale Ann Intern Med 137 2002 526 528
45. M.D. Krahn, G. Naglie, D. Naimark, D.A. Redelmeier, and A.S. Detsky Primer on medical decision analysis, part 4: analyzing the model and interpreting the results Med Decis Making 17 1997 142 151
46. S.G. Pauker, and J.P. Kassirer The threshold approach to clinical decision making N Engl J Med 302 1980 1109 1117
47. A.D. Paltiel Model-based drug evaluation in chronic disease: promise, pitfalls, and positioning Drug Info J 35 2001 131 139
48. M.C. Weinstein, P.G. Coxson, L.W. Williams, T.M. Pass, W.B. Stason, and L. Goldman Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model Am J Public Health 77 1987 1417 1426
49. Hay J, Jackson J. Proceedings of the Advisory Panel Meeting and Conference on Pharmacoeconomic Issues, Panel 2: Methodological Issues in Conducting Pharmacoeconomic Evaluations - Modeling Studies. Value Health 1999;2:78-81.
50. C.L. Pashos E.G. Klein L.A. Wanke ISPOR Lexicon 1998 International Society for Pharmacoeconomics and Outcomes Research Princeton (NJ)